265 related articles for article (PubMed ID: 10181724)
1. Clinical studies of safety and effectiveness of orphan products; availability of grants; request for applications--FDA. Notice.
Fed Regist; 1998 Aug; 63(150):41855-9. PubMed ID: 10181724
[TBL] [Abstract][Full Text] [Related]
2. Clinical studies of safety and effectiveness of orphan products; availability of grants; request for applications. Department of Health and Human Services (HHS), Public Health Service (PHS), Food and Drug Administration (FDA). Notice.
Fed Regist; 1999 Jul; 64(141):40012-6. PubMed ID: 10558579
[TBL] [Abstract][Full Text] [Related]
3. Developing treatments for inborn errors: incentives available to the clinician.
Haffner ME
Mol Genet Metab; 2004 Apr; 81 Suppl 1():S63-6. PubMed ID: 15050976
[TBL] [Abstract][Full Text] [Related]
4. Orphan Drug Act on congressional agenda.
von Oehsen WH
Physician Exec; 1989; 15(3):34-5. PubMed ID: 10313123
[TBL] [Abstract][Full Text] [Related]
5. FDA publishes conflict of interest rules for clinical trials. Food and Drug Administration.
James JS
AIDS Treat News; 1998 Mar; (No 290):8. PubMed ID: 11365123
[TBL] [Abstract][Full Text] [Related]
6. Creation and development of the public service orphan drug Human Botulism Immune Globulin.
Arnon SS
Pediatrics; 2007 Apr; 119(4):785-9. PubMed ID: 17403850
[TBL] [Abstract][Full Text] [Related]
7. Characteristics of orphan drug applications that fail to achieve marketing approval in the USA.
Heemstra HE; Leufkens HG; Rodgers RP; Xu K; Voordouw BC; Braun MM
Drug Discov Today; 2011 Jan; 16(1-2):73-80. PubMed ID: 21094692
[TBL] [Abstract][Full Text] [Related]
8. Availability of additional HRSA competitive grants. Health Resources and Services Administration, HHS. Notice of availability of funds.
Fed Regist; 1999 Apr; 64(73):18915-8. PubMed ID: 10558550
[TBL] [Abstract][Full Text] [Related]
9. Prescription Drug Marketing Act Pedigree Requirements; effective date and compliance policy guide; request for comment. Final rule; announcement of effective date; notice of availability; request for comment.
Food and Drug Administration, HHS
Fed Regist; 2006 Jun; 71(114):34249-51. PubMed ID: 16795943
[TBL] [Abstract][Full Text] [Related]
10. The Orphan Drug Act and the Federal Government's Orphan Products Development Program.
Finkel MJ
Public Health Rep; 1984; 99(3):313-6. PubMed ID: 6429731
[TBL] [Abstract][Full Text] [Related]
11. Grants for Centers for Research and Demonstration of Health Promotion and Disease Prevention; program announcement and notice of availability of funds for fiscal year 1988--CDC.
Fed Regist; 1988 Apr; 53(73):12595-9. PubMed ID: 10314276
[No Abstract] [Full Text] [Related]
12. Two decades of orphan product development.
Haffner ME; Whitley J; Moses M
Nat Rev Drug Discov; 2002 Oct; 1(10):821-5. PubMed ID: 12360259
[TBL] [Abstract][Full Text] [Related]
13. Health financing research and demonstration grants; availability of funds for grants--HCFA. General notice.
Fed Regist; 1983 Nov; 48(218):51538-45. PubMed ID: 10263116
[TBL] [Abstract][Full Text] [Related]
14. Orphan drug development in the United States.
Groft SC
CPJ; 1985 May; 118(5):219-22. PubMed ID: 10271306
[TBL] [Abstract][Full Text] [Related]
15. International Conference on Harmonisation; guidance on S7A safety pharmacology studies for human pharmaceuticals; availability. Notice.
Food and Drug Administration, HHS
Fed Regist; 2001 Jul; 66(135):36791-2. PubMed ID: 12356097
[TBL] [Abstract][Full Text] [Related]
16. Orphan products: drugs and devices for rare diseases.
Pillar B
Nurs Econ; 1993; 11(2):99-102. PubMed ID: 8502310
[TBL] [Abstract][Full Text] [Related]
17. International Conference on Harmonisation; guidance on E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs; availability. Notice.
Food and Drug Administration, HHS
Fed Regist; 2005 Oct; 70(202):61134-5. PubMed ID: 16237860
[TBL] [Abstract][Full Text] [Related]
18. Opportunity to request change in classification of continuous ventilator--FDA. Notice; final rule-related.
Fed Regist; 1983 Jun; 48(118):27723-4. PubMed ID: 10289467
[TBL] [Abstract][Full Text] [Related]
19. Promoting, improving and accelerating the drug development and approval processes.
Graul AI
Drug News Perspect; 2007; 20(1):45-55. PubMed ID: 17332899
[TBL] [Abstract][Full Text] [Related]
20. Experimental use and the Orphan Drug Act: a biotechnology conundrum.
Koivuniemi PJ
Nat Biotechnol; 1996 Apr; 14(4):511-2. PubMed ID: 9630930
[No Abstract] [Full Text] [Related]
[Next] [New Search]
